Cajal Therapeutics develops novel small molecule and RNA medicines targeting iron homeostasis for systemic and neurologic diseases. Their therapies aim to restore iron balance, addressing conditions like anemias of inflammation and neurodegenerative disorders. The lead program focuses on an iron mobilizer to restore essential iron transport for cellular processes.
Funding
$95.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's are characterized by progressive cellular degeneration, yet effective treatments that address the underlying causes remain elusive. Identifying relevant drug targets is challenging due to the complexity of the brain and the limitations of traditional drug discovery methods.
Solution
Cajal Neuroscience employs advanced technologies to discover novel drug targets for neurodegenerative diseases. The company integrates high-throughput microscopy, functional genomics, and multi-omics analyses to map the cellular landscape of the brain and identify key drivers of degeneration. By understanding the molecular mechanisms underlying these diseases, Cajal Neuroscience aims to develop therapeutics that can slow or reverse disease progression.
Target Audience
The target audience includes pharmaceutical companies and research institutions focused on developing treatments for neurodegenerative diseases.
Features
- High-throughput microscopy for detailed cellular imaging and analysis
- Functional genomics to identify genes and pathways involved in neurodegeneration
- Multi-omics analyses to integrate diverse datasets and gain a comprehensive understanding of disease mechanisms
- Target identification based on cellular and molecular insights